Predictive Oncology
COMPANY OVERVIEW
Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), is a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, The company applies smart tumor profiling and an AI platform to extensive genomic and biomarker patient data sets. This enables them to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow.
HELOMICS
POAI’s unique molecular information platform identifies the biomarkers of a living tumor using a set of genomic and functional tests that determine how a specific tumor responds to drugs. The company then compares that tumor profile with its extensive knowledge base, generating a roadmap for the oncologist to personalize treatment.
TUMORGENESIS
Predictive’s TumorGenesis tumor modeling approach identifies biomarkers indicative of cancer by “fooling” cancer cells into thinking they’re still growing inside the patient. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolates and helps categorize a patient’s tumor samples to enable development of patient-specific treatment options.
According to MarketWatch, the global cell culture media market is growing at a healthy 8.4% CAGR, driven mainly by the increased use of biological based drugs such as immune therapies, and is expected to reach US $2,360 Million by 2024.
The Company believes their novel TumorGenesis tumor modeling could provide pharmaceutical companies newfound ability for more effective and expeditious drug development and subsequently improve patient outcomes.
SKYLINE MEDICAL
Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility,
Skyline’s STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids, which results in:
Reducing overhead costs to hospitals and surgical centers
Improving their Occupational Safety and Health Administration (OSHA) and other regulatory compliance
Enhancing the efficiency of the operating room and thereby making surgeries more profitable
Additionally, the STREAMWAY system is eco-friendly as it addresses the numerous and potentially disease infected canisters that go into U.S. landfills every year. These tainted canisters—which are generally made of plastic—can take centuries to biodegrade, but with installations of the STREAMWAY System, the number of these canisters can be significantly reduced.
About Predictive Oncology Inc.
Predictive Oncology operates through three subsidiaries: Helomics, which provides tumor-analysis services for treatment personalization and new drug development; TumorGenesis, which is developing patient-derived tumor models for precision drug testing; and Skyline Medical, which markets a US Food and Drug Administration-approved system for automated medical fluid disposal.
